Does Metformin Increase Paraoxonase Activity in Patients with the Metabolic Syndrome? Additional Data from the MEFISTO Study

Clinical and Translational Science

Volumn 5, Issue 3, 2012, Pages 265-268

  Meaney, Eduardo ^a,b   Sierra Vargas, Patricia ^c   Meaney, Alejandra ^b   Guzmán Grenfell, Martín ^c   Ramírez Sánchez, Israel ^a   Hicks, Juan Jose ^c   Olivares Corichi, Ivonne ^a   Ceballos, Guillermo ^a  

^a CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Carotid intima media thickness; HDL cholesterol; Metabolic syndrome; Metformin; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN;

ARTERIAL WALL THICKNESS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; METABOLIC SYNDROME X; OPEN STUDY; PRIORITY JOURNAL;

EID: 85027937260     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2012.00391.x     Document Type: Article

References (20)

1. Assman G, Gotto AM, Jr. Atherosclerosis: evolving vascular biology and clinical implications. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004; 109: III-8-III-14.
2. Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Pública Méx. 2010; 52(Suppl 1): 44-53.
3. Meaney E, Lara-Esqueda A, Ceballos-Reyes GM, Asbun J, Vela A, Martínez-Marroquín Y. Cardiovascular risk factors in the urban Mexican population: the FRIMEX study. Public Health. 2007; 121: 378-384.
4. Sánchez-Castillo CP, Velásquez-Monroy O, Lara-Esqueda A, Berber A, Sepúlveda J, Tapia-Conyer R, James WP. Diabetes and hypertension increases in a society with abdominal obesity: results of the Mexican National Health Survey 2000. Public Health Nutr. 2004; 8: 53-60.
5. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, Hernández-Avila M, Sepulveda-Amor J. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México : Instituto Nacional de Salud Pública; 2006.
6. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A, Shamah-Levy T, Rauda J, Ávila-Burgos L, Villalpando S, Lazcano E. Metabolic syndrome in Mexican adults. Results from the National Health and Nutrition Survey 2006. Salud Pública Méx. 2010; 52(Suppl 1): 11-18.
7. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005; 5: 379-387.
8. Meaney E, Vela A, Samaniego V, Meaney A, Asbún J, Zempoalteca JC, Zarate E, Mendoza E, Guzman M, Hicks JJ, et al. Metformin, arterial function, intima-media, thickness and nitroxidation in metabolic syndrome: the MEFISTO study. Clin Exp Pharmacol Physiol. 2008; 35: 895-903.
9. Nicholls SJ, Nissen SE. New targets of high density lipoprotein therapy. Curr Opin Lipidol. 2007; 18: 421-426.
10. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough G, Watson A, Reddy S, Sevanian A, Foranow G, Fogelman A. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000; 41: 1495-1508.
11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
12. Browne R, Koury S, Marion S, Wilding G, Muti P, Trevisan M. Accuracy and biological variation of human serum paraoxonase I activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem. 2007; 53: 310-317.
13. Alison Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation. 2006; 114: 597-605.
14. Gupta N, Gill K, Singh S. Paraoxonases: structure, gene plymorphism & role in coronary artery disease. Indian J Med Res. 2009; 130: 361-368.
15. Costa LG, Vitallone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005; 69: 541-550.
16. Coll B, Van Wijk JPH, Parra S, Castro Cabezas M, Hoepelman IM, Alonso-Villaverde C, de Koening E, Camps J, Ferre N, Raberlink T, et al. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. Eur J Pharmacol. 2006; 544: 104-110.
17. Koçer D, Muhtaroulu S, Bayram F. Effects of metformin on malondialdehyde level and paraoxonase 1 activity in patients with polycystic ovary syndrome. Erciyes Med J. 2008; 30: 6570.
18. Cece H, Yazgan P, Karakas E, Karakas O, Demirkol A, Toru I, Aksoy N. Carotid intima-media thickness and paraoxonase activity in patients with ankylosing spondylitis. Clin Invest Med. 2011; 34: E225.
19. Hurst RT, Ng DW, Kendall C, Khandheria B. Clinical use of carotid intima-media thickness: review of the literature. J Am Soc Echocardiogr. 2007; 20: 907-914.
20. Yang W-I, Lee S-H, Ko Y-G, Kang S-M, Choi D, Ha J-W, Honh M-K, Chung N, Shim W-H, Cho S-Y, et al. Relationship between paraoxonase-1 activity, carotid intima-media thickness and arterial stiffness in hypertensive patients. J Hum Hypertens. 2010; 24: 492-494.